Association Between BCR-ABL Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia and Cardiovascular Events, Major Molecular Response, and Overall Survival - Concepedia

Concepedia

Publication | Open Access

Association Between BCR-ABL Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia and Cardiovascular Events, Major Molecular Response, and Overall Survival

DOI Full Paper Access

186

Citations

33

References

2016

Year

Jonathan Douxfils, Hélène Haguet, François Mullier, C Chatelain, Carlos Graux, Jean‐Michel Dogné

Abstract

Dasatinib, nilotinib, and ponatinib increase vascular occlusive events. New-generation TKIs improve MMR but not the overall survival at 1 year in patients with CML.

References

	Year	Citations

Page 1